Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists
The DOI matches its Crossref record; 128 of the 132 references it cites were found in a registry or an index, and 4 are not checked yet.
Abstract
Vancomycin is a glycopeptide antibiotic that has been in clinical use for nearly 50 years as a penicillin alternative to treat penicillinase-producing strains of Staphylococcus aureus. It is one of the most widely used antibiotics in the United States for the treatment of serious gram-positive infections involving methicillin-resistant S. aureus (MRSA).1 Early use of vancomycin was associated with a number of adverse effects, including infusion-related toxicities, nephrotoxicity, and possible ototoxicity. Upon further investigation, it appears that the impurities in early formulations of vancomycin caused many of these adverse events.1–4 Its overall use was curtailed significantly with the development of semisynthetic penicillins (e.g., methicillin, oxacillin, nafcillin) that were considered less toxic.1–4 However, the steady rise in the number of MRSA infections since the early 1980s has once again brought vancomycin into the forefront as the primary treatment for infections caused by this organism....
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Principles and Practice of Infectious Diseases.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-818_5 · Cited by 12,025
(2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200405-644st · Cited by 5,877
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908
Self-citationHundahl, S. A., Fleming, I. D., Fremgen, A. M., & Menck, H. R. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981215)83:12<2638::aid-cncr31>3.0.co;2-1 · Cited by 1,836
Autoinduction and signal transduction in the regulation of staphylococcal virulence
Novick, R. P. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03526.x · Cited by 1,280 · cited 1×
“aureus that is responsible for orchestrating the expression of adherence factors, biofilm production, tolerance to vancomycin, and virulence factors.(66) The agr locus has been a subject of intense study because there appears to be a relationship between polymorphism in this gene cluster and patient response to vancom…”
BackgroundMartindale. The Extra Pharmacopoeia.
(1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-5-687_2 · Cited by 1,111
Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'
Drusano, G. L. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro862 · Cited by 930
Hidayat, L. K., Hsu, D. I., Quist, R., Shriner, K. A., & Wong-Beringer, A. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.19.2138 · Cited by 860 · cited 4×
“Hidayat et al.(53) prospectively investigated the efficacy and toxicity of adjusting vancomycin troughs to achieve an unbound concentration of at least four times the MIC.”
BackgroundInfluentialLevine, D. P. (2006) · Clinical Infectious Diseases · doi:10.1086/491709 · Cited by 838
Self-citationSakoulas, G., Moise-Broder, P. A., Schentag, J., Forrest, A., Moellering, R. C., & Eliopoulos, G. M. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.6.2398-2402.2004 · Cited by 836 · cited 2×
“Sakoulas et al.(52) reported a significant correlation between vancomycin susceptibilities and patient outcome.”
BackgroundSelf-citation
Research works printed but not linked: 5
- Virgincar, 2004, Glycopeptides (dalabavancin, oritavancin, teicoplanin, vancomycin), 181
- Cooper, 1986, The development of vancomycin, 1
- Geraci, 1977, Vancomycin, Mayo Clin Proc, 52, 631
- Boffi El Amari, 2004, High versus standard dose vancomycin for osteomyelitis, Scand J Infect Dis., 36, 712
- Dangerfield, 1960, Clinical use of vancomycin, Antimicrob Agents Chemother, 61, 428
Cited by
Items 801–900 of 1,002
New therapy options for MRSA with respiratory infection/pneumonia
Ramírez, P., Fernández‐Barat, L., & Torres, A. (2012) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e3283509cfa · Cited by 15
“Frequent use of other nephrotoxic drugs in critically ill patients and the need to achieve high plasma levels of vancomycin increase the risk of nephrotoxicity in patients treated with vancomycin [25].”
BackgroundAlaniz, C., & Pogue, J. M. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1r221 · Cited by 15
Vancomycin Tissue Pharmacokinetics in Patients with Lower-Limb Infections via In Vivo Microdialysis
Housman, S. T., Bhalodi, A. A., Shepard, A. K., Nugent, J. F., & Nicolau, D. P. (2015) · Journal of the American Podiatric Medical Association · doi:10.7547/14-033 · Cited by 15
Heisel, R., Sutton, R. R., Mascara, G. P., Winger, D. G., Weber, D. R., Lim, S. H., & Oleksiuk, L. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1306645 · Cited by 15
Rajon, K., Vaillancourt, R., Varughese, N., & Villarreal, G. (2017) · Pharmacy Practice · doi:10.18549/pharmpract.2017.02.887 · Cited by 15
“Pharmacy Practice 2017 Apr-Jun;15(2):887.”
Vancomycin Area Under the Curve Simplified
Lewis, P. O. (2018) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000500 · Cited by 15
60 Plus Years Later and We Are Still Trying to Learn How to Dose Vancomycin
Rodvold, K. A. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz467 · Cited by 17
Ortwine, J. K., Zasowski, E. J., Pogue, J. M., Hanni, C. M., Giuliano, C., Casapao, A. M., Mynatt, R. P., & Rybak, M. J. (2019) · Infectious Diseases and Therapy · doi:10.1007/s40121-019-00268-3 · Cited by 15
Self-citationStatus Toward the Implementation of Precision Dosing in Children
Barrett, J. S., Barrett, R. F., & Vinks, A. A. T. M. M. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1830 · Cited by 18
Continuous infusion versus intermittent infusion vancomycin in a burn center intensive care unit
Schlobohm, C. J., Zhu, E., & Duby, J. J. (2021) · Burns · doi:10.1016/j.burns.2021.08.016 · Cited by 15
Alsowaida, Y. S., Kubiak, D. W., Dionne, B., Kovacevic, M. P., & Pearson, J. C. (2022) · Antibiotics · doi:10.3390/antibiotics11091239 · Cited by 15
“References [19,20] are cited in the supplementary materials.”
BackgroundEvaluation of the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia
Usery, J. B., Vo, N. H., Finch, C. K., Cleveland, K. O., Gelfand, M. S., & Self, T. H. (2014) · The American Journal of the Medical Sciences · doi:10.1097/maj.0000000000000338 · Cited by 17
Wang, J., Wu, H.-S., Weng, C.-M., Hsu, L., & Wang, F. (2013) · BMC Infectious Diseases · doi:10.1186/1471-2334-13-182 · Cited by 15
“causative MRSA isolates have a vancomycin MIC > 1 mg/L [10].”
BackgroundComparison of Continuous and Intermittent IV Infusion of Vancomycin: Systematic Review
Ensom, M. H. H., Man, S. S. K., & Carr, R. R. (2010) · The Canadian Journal of Hospital Pharmacy · doi:10.4212/cjhp.v63i5.949 · Cited by 15
“However, the correlation between high vancomycin concentrations in serum and nephrotoxicity and ototoxicity is poor.(3,5) Pharmacokinetic studies have demonstrated shorter time to and longer duration of target serum concentrations with continuous infusion than with intermittent administration for equivalent total dail…”
BackgroundInfluentialLee, J. P., & Dang, A. T. (2011) · Spinal Cord · doi:10.1038/sc.2011.82 · Cited by 15
Antimicrobial resistance: Consideration as an adverse drug event
Martin, S. J., Micek, S. T., & Wood, G. C. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181de0c26 · Cited by 17
Aprazamento de medicamentos por enfermeiros em prescrições de hospital sentinela
da Silva, L. D., de Matos, G. C., Barreto, B. G., & de Albuquerque, D. C. (2013) · Texto & Contexto - Enfermagem · doi:10.1590/s0104-07072013000300019 · Cited by 15
Griffin, S. P., & Nelson, J. E. (2016) · Progress in Transplantation · doi:10.1177/1526924816667950 · Cited by 15
Neutropenia is independently associated with sub-therapeutic serum concentration of vancomycin
Choi, M. H., Choe, Y. H., Lee, S.-G., Jeong, S. H., & Kim, J. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.12.021 · Cited by 15
Predictors of Adverse Outcomes in Children With Staphylococcus aureus Bacteremia
Kumarachandran, G., Johnson, J. K., Shirley, D.-A. T., Graffunder, E. M., & Heil, E. L. (2017) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-22.3.218 · Cited by 18
Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections
Galluzzo, M., D’Adamio, S., Bianchi, L., & Talamonti, M. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1420162 · Cited by 15
“toxicities associated have led to the recent development of several novel anti-MRSA molecules [4,6].”
BackgroundKassel, L. E., Matre, E. T. V., Foster, C. J., Fish, D. N., Mueller, S. W., Sherman, D. S., Wempe, M. F., MacLaren, R., Neumann, R. T., & Kiser, T. H. (2018) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2156 · Cited by 15
The comparative risk of acute kidney injury of vancomycin relative to other common antibiotics
Gaggl, M., Pate, V., Stürmer, T., Kshirsagar, A. V., & Layton, J. B. (2020) · Scientific Reports · doi:10.1038/s41598-020-73687-9 · Cited by 16
O'Riordan, W., Green, S., Mehra, P., Anda, C. S. D., Fang, E., & Prokocimer, P. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit617 · Cited by 15
“Despite the workhorse status of vancomycin [1, 10], the emergence of strains with rising minimal inhibitory concentrations (MICs), as well as vancomycin-intermediate and vancomycin-resistant S.”
BackgroundImportance of Decision Support Implementation in Emergency Department Vancomycin Dosing
Faine, B. A., Mohr, N. M., Harland, K. K., Rolfes, K., Porter, B. A., & Fuller, B. M. (2015) · Western Journal of Emergency Medicine · doi:10.5811/westjem.2015.4.25760 · Cited by 15
Wright, D. F. B., Al-Sallami, H. S., Jackson, P. M., & Reith, D. M. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03749.x · Cited by 15
Antimicrobial use in a critical care unit: a prospective observational study
Candeloro, C. L., Kelly, L. M., Bohdanowicz, E., Martin, C. M., & Bombassaro, A. M. (2011) · International Journal of Pharmacy Practice · doi:10.1111/j.2042-7174.2011.00176.x · Cited by 15
“aureus infections will promote stewardship through dose optimization to maximize efficacy and minimize risks associated with suboptimal dosing.([15,16]) The collection of microbiological data in the current analysis was restricted to patients treated for infection with documented microorganisms, with the exception of…”
BackgroundSignificant publications on infectious diseases pharmacotherapy in 2012
Bowers, D. R., Hunter, A. S., Jacobs, D. M., Kuper, K. M., Musick, W. L., Perez, K. K., Shah, D. N., & Schilling, A. N. (2013) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp130129 · Cited by 15
Lee, H., Kim, Y., Kim, J., Kim, S., & Jeong, T. (2025) · Journal of Medical Internet Research · doi:10.2196/63983 · Cited by 15
“To simplify monitoring, trough serum vancomycin concentrations (15-20 mg/L) were previously recommended as a surrogate marker for AUC24/MIC, but the correlation between vancomycin’s AUC24/MIC and trough concentration remains modest [7,8].”
Electrospun Chitosan-Based Nanofibrous Coating for the Local and Sustained Release of Vancomycin
Serpelloni, S., Williams, M. E., Caserta, S., Sharma, S., Rahimi, M., & Taraballi, F. (2024) · ACS Omega · doi:10.1021/acsomega.3c08113 · Cited by 14
Liu, J., Zhang, X., Liang, G., Jianping, Z., Yang, Y., Zheng, Y., Han, Y., Yu, L., Zhao, Y., & Yu, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1370040 · Cited by 14
Kang, W., Zou, T., Liang, Y., Lei, H., Zhang, R., Kang, J., Sun, Z., Li, X., Ge, S., & Zhang, C. (2024) · Dental Materials · doi:10.1016/j.dental.2024.08.005 · Cited by 15
Hu, T., Ding, X. Z., Han, F., & An, Z. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1549500 · Cited by 14
Clinical Experience With Daptomycin for Outpatient Parenteral Antibiotic Therapy
Larioza, J., Brown, R. B., & Girard, A. W. (2011) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31821e1e6b · Cited by 14
Pharmacological Management of Pediatric Patients With Sepsis
Simmons, M. L., Durham, S. H., & Carter, C. W. (2012) · AACN Advanced Critical Care · doi:10.1097/nci.0b013e31826ddccd · Cited by 14
Rosini, J. M., Davis, J. J., Muenzer, J. R., Levine, B. J., Papas, M. A., Comer, D., & Arnold, R. (2016) · Academic Emergency Medicine · doi:10.1111/acem.12934 · Cited by 14
Dosage Adjustments Related to Young or Old Age and Organ Impairment
Burris, J. F., Tortorici, M. A., Mandić, M., Neely, M. N., & Reed, M. D. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.816 · Cited by 14
Seng, J. J. B., Yong, M. H. A., Peh, Z. X., Soong, J. L., & Tan, M. H. (2018) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-018-0670-4 · Cited by 14
Charoensareerat, T., Chaijamorn, W., Boonpeng, A., Srisawat, N., Pummangura, C., & Pattharachayakul, S. (2019) · Journal of Critical Care · doi:10.1016/j.jcrc.2019.07.008 · Cited by 14
A Population Pharmacokinetics Model for Vancomycin Dosage Optimization Based on Serum Cystatin C
Lu, J., Chen, M., Lv, C., Zhang, R., Lu, H., Cheng, D.-H., Tang, S., & Liu, T. (2020) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-020-00621-9 · Cited by 14
Sulaiman, K. A. A., Alshaya, A. I., Aljuhani, O. A., Alsaeed, A., Alshehri, N., Vishwakarma, R. K., Alzahrani, H., Althewaibi, S., Alghamdi, N. A., Alhelal, K., et al. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06840-y · Cited by 17
Uster, D. W., & Wicha, S. G. (2022) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12782 · Cited by 17
Junaid, T., Wu, X., Thanukrishnan, H., & Venkataramanan, R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814276-9.00030-1 · Cited by 21
Hamilton, L. A., Wood, G. C., Magnotti, L. J., Croce, M. A., Martin, J. B., Swanson, J. M., Boucher, B. A., & Fabian, T. C. (2012) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0b013e318250911b · Cited by 14
“In addition, there are no good outcome data in critically ill trauma patients who are a unique intensive care unit (ICU) population in terms of demographics, pharmacokinetics, and susceptibility to VAP.13 Based on pharmacokinetic data and our clinical experience, vancomycin has been dosed aggressively at our center si…”
BackgroundMethodInfluentialGentamicin Pharmacokinetics and Pharmacodynamics during Short-Daily Hemodialysis
Decker, B. S., Mohamed, A., Chambers, M., Kraus, M. A., Moe, S. M., & Sowinski, K. M. (2012) · American Journal of Nephrology · doi:10.1159/000339937 · Cited by 15
Use of Antibacterial Agents in Renal Failure
Gilbert, B. C., Robbins, P., & Livornese, L. L. (2011) · Medical Clinics of North America · doi:10.1016/j.mcna.2011.03.010 · Cited by 14
Jin, S. J., Yoon, J. H., Ahn, B. S., Chung, J. A., & Song, Y. G. (2014) · Infection and Chemotherapy · doi:10.3947/ic.2014.46.1.21 · Cited by 14
“In a recent consensus review, it was recommended that the trough concentration should always be maintained above 10 mg/L to avoid development of resistance, and for a pathogen with a MIC of 1 mg/L, the trough concentration would have to be at least 15 mg/L to achieve the target AUC24/MIC value of 400 [23].”
Williams, A. W., Newman, P. M., Ocheltree, S., Beaty, R. S., & Hassoun, A. (2015) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-20.6.476 · Cited by 14
An Evaluation of Systemic Vancomycin Dosing in Obese Patients
Kubiak, D. W., Alquwaizani, M., Sansonetti, D., Barra, M. E., & Calderwood, M. S. (2015) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofv176 · Cited by 14
“namic target of an area under the concentration-time curve/ minimum inhibitory concentration (MIC) >400 when the MIC is ≤1 mcg/mL for Staphylococcus aureus [3].”
BackgroundEvaluation of Vancomycin Dosing in Pediatric Cystic Fibrosis Patients
McDade, E. J., Hewlett, J. L., Moonnumakal, S. P., & Baker, C. J. (2016) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-21.2.155 · Cited by 14
“Doses administered prior to VTC, median (range) 5 (3-32) 4 (3-49)”
BackgroundPhillips, C. J., Wisdom, A. J., McKinnon, R. A., Woodman, R. J., & Gordon, D. (2018) · Infection and Drug Resistance · doi:10.2147/idr.s176519 · Cited by 16
Ikeda, S., Uchiyama, K., Minegishi, Y., Ohno, K., Nakamura, M., Yoshida, K., Fukushima, K., Takahira, N., & Takaso, M. (2018) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-018-1033-5 · Cited by 14
Evaluation of efficacy and nephrotoxicity during vancomycin therapy: A retrospective study in China
Wang, L., Yuan, Q., Tan, M., Xie, S., Wu, J., Song, X., & Wang, C. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7188 · Cited by 14
He, N., Su, S., Yan, Y., Liu, W., & Zhai, S. (2019) · Annals of Pharmacotherapy · doi:10.1177/1060028019887363 · Cited by 14
Flannery, A. H., Hammond, D. A., Oyler, D. R., Li, C., Wong, A., Smith, A. P., Yeo, Q. M., Chaney, W., Pfaff, C., Plewa-Rusiecki, A. M., et al. (2020) · Infectious Diseases Research and Treatment · doi:10.1177/1178633720952078 · Cited by 14
Supratherapeutic vancomycin levels after trauma predict acute kidney injury and mortality
Ley, E. J., Liou, D. Z., Singer, M. B., Mirocha, J., Srour, M. K., Bukur, M., Margulies, D. R., & Salim, A. (2013) · Journal of Surgical Research · doi:10.1016/j.jss.2013.04.047 · Cited by 14
“[1] Rybak M, Lomaestro B, Rotschafer JC, et al.”
BackgroundMethodInfluentialPhilippe, M., Neely, M. N., Bertrand, Y., Bleyzac, N., & Goutelle, S. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0448-6 · Cited by 14
Significant publications on infectious diseases pharmacotherapy in 2011
Tran, T. T., Beyda, N. D., Biehle, L. R., Cottreau, J. M., Echevarria, K. L., Musick, W. L., Perez, K. K., & Schilling, A. N. (2012) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp120151 · Cited by 14
A protocolized approach to vancomycin dosing in conventional hemodialysis
Panais, R., Hirsch, D. J., Dipchand, C. S., Storsley, L. J., & Finkle, S. N. (2010) · Journal of Nephrology · doi:10.1093/joneph/23.5.569 · Cited by 14
Panday, P. V. N., & Sturkenboom, M. G. G. (2009) · Clinical Infectious Diseases · doi:10.1086/648506 · Cited by 14
Makmor‐Bakry, M., Ahmat, A. N. M. F., Shamsuddin, A. F., Lau, C. L., & Ramli, R. (2019) · Anaesthesiology Intensive Therapy · doi:10.5114/ait.2019.87362 · Cited by 13
“A recent clinical guideline recommends a higher serum trough concentration (15–20 μg mL-1) for patients with complicated MRSA bacteremia [2].”
BackgroundVancomycin powder in total joint replacement
Mancino, F., Gant, V. A., Meek, D. R. M., & Haddad, F. S. (2023) · The Bone & Joint Journal · doi:10.1302/0301-620x.105b8.bjj-2023-0675 · Cited by 13
Hall, R. G., Blaszczyk, A. T., Thompson, K. A., Brouse, S. D., Giuliano, C. A., Frei, C. R., Forcade, N. A., Mortensen, E. M., Bell, T., Bedimo, R., et al. (2014) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12203 · Cited by 13
“The guideline-recommended vancomycin trough concentration range of 15–20 mg/L was used to define the cut-off of 15 mg/L.(5) Vancomycin trough concentrations above this cut-off are also associated with nephrotoxicity.”
BackgroundMethodInfluentialAntimicrobial resistance in internal medicine wards
Menichetti, F., & Tagliaferri, E. (2012) · Internal and Emergency Medicine · doi:10.1007/s11739-012-0828-3 · Cited by 13
“Therapeutic drug monitoring (TDM) is recommended for glycopeptides and trough level should be 15–20 mg/L for vancomycin and 20–30 mg/L for teicoplanin [3].”
BackgroundMethodAlcalá‐Cerra, G., Paternina-Caicedo, Á. J., Moscote‐Salazar, L. R., Gutiérrez-Paternina, J. J., & Niño-Hernández, L. M. (2014) · Revista Española de Cirugía Ortopédica y Traumatología · doi:10.1016/j.recot.2013.10.004 · Cited by 13
Infectious Diseases Pharmacotherapy for Children With Cystic Fibrosis
Molloy, L. M., & Nichols, K. R. (2015) · Journal of Pediatric Health Care · doi:10.1016/j.pedhc.2015.07.010 · Cited by 15
Sato, Y., Hiramatsu, K., Suzuki, Y., Tanaka, R., Kaneko, T., Nonoshita, K., Ogata, M., Kadota, J., & Itoh, H. (2017) · Chemotherapy · doi:10.1159/000481725 · Cited by 13
Optimizing vancomycin dosage regimens in relation to high-flux haemodialysis
Hui, K., Patel, K., Nalder, M., Nelson, C., Buising, K. L., Pedagogos, E., Kong, D. C. M., & Kirkpatrick, C. M. J. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky371 · Cited by 13
Rodríguez, N., Gómez, M., Rico, N., Campistol, J. M., & Maduell, F. (2018) · Artificial Organs · doi:10.1111/aor.13368 · Cited by 13
Emerging and re-emerging infectious disease in otorhinolaryngology
SCASSO, F., FERRARI, G., Vincentiis, G. C. D., Arosio, A. D., Bottero, S., CARRETTI, M., CIARDO, A., Cocuzza, S. G., COLOMBO, A., Conti, B., et al. (2018) · Acta Otorhinolaryngologica Italica · doi:10.14639/0392-100x-suppl.1-38-2018 · Cited by 14
Singer, B., Stevens, R. W., Westley, B. P., & Nicolau, D. P. (2019) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxz258 · Cited by 13
Pires, F. R., de Paula, S. I., Delgado, A. F., de Carvalho, W. B., Duarte, N. J. C., Morales, R., & Santos, S. R. C. J. (2020) · Revista Brasileira de Terapia Intensiva · doi:10.5935/0103-507x.20200067 · Cited by 13
“2020;32(3):391-397 vancomycin concentration in critically ill adult and pediatric patients with infection caused by nosocomial pathogens.”
BackgroundInfluentialHuang, J., Wang, X., Hao, C., Yang, W., Zhang, W., Liu, J., & Qu, H. (2021) · Internal and Emergency Medicine · doi:10.1007/s11739-021-02699-8 · Cited by 15
Yoo, R., So, H., Seo, E., Kim, M., & Lee, J. (2021) · PLoS ONE · doi:10.1371/journal.pone.0247714 · Cited by 13
“There is a controversy about a limited activity of vancomycin against MRSA isolates with a MIC at the high end of the susceptibility range [22, 23]; vancomycin MIC� 1.”
BackgroundFerreira, A., Martins, H., Oliveira, J. C., Lapa, R. A. S., & Vale, N. (2021) · Life · doi:10.3390/life11111130 · Cited by 15
Kim, Y., Kim, S.-H., Park, J., & Lee, H. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12020163 · Cited by 13
“TDM for vancomycin in this study was performed to maintain minimum serum trough concentrations >10 mg/L to avoid the development of resistance according to the previous guidelines [14].”
BackgroundMethodPalmer, L. B., & Smaldone, G. C. (2022) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2021.0023 · Cited by 13
Al-Sroji, R. Y., Laham, S. A., & Almandili, A. (2023) · Pharmaceutical Biology · doi:10.1080/13880209.2023.2204916 · Cited by 13
“Although the use of high-doses of VCM is not approved by regulatory authorities, this use is reaching 15–20mg/L during the provision of health care due to emerging drug resistance (Martin et al. 2010).”
BackgroundBarnes, B., & SAMPSON, D. A. (2010) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2010.00571.x · Cited by 18
Sidrim, J. J. C., Teixeira, C. E. C., Cordeiro, R. D. A., Brilhante, R. S. N., Castelo‐Branco, D. D. S. C. M., Bandeira, S. P., de Alencar, L. P., de Oliveira, J. S., Monteiro, A. J., Moreira, J. L. B., et al. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.12.012 · Cited by 13
Yang, Y., McBride, M. V., Rodvold, K. A., Tverdek, F. P., Trese, A. M., Hennenfent, J. A., Schiff, G. D., Lambert, B. L., & Schumock, G. T. (2010) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp090563 · Cited by 16
Shoji, H., Maeda, M., Shirakura, T., Takuma, T., Ugajin, K., Fukuchi, K., Ishino, K., & Niki, Y. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2015.07.013 · Cited by 13
“[3] Rybak M, Lomaestro B, Rotschafer JC, Moellering Jr R, Craig W, Billeter M, et al.”
BackgroundInfluentialZelenitsky, S. A., Alkurdi, N., Weber, Z., Ariano, R. E., & Zhanel, G. G. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01472-10 · Cited by 13
“Furthermore, a 2009 consensus review of vancomycin therapeutic monitoring by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists recommended more aggressive dosing to achieve serum troughs of 10 or 15 to 20 mg/liter for serio…”
BackgroundSuleyman, G., & Zervos, M. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1127349 · Cited by 18
The pharmacokinetics of vancomycin in patients with severe acute pancreatitis
He, J., Mao, E., Feng, J., Jiang, H., Yang, W., & Chen, E. (2016) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-016-2018-0 · Cited by 13
“Due to its narrow therapeutic window, optimizing vancomycin therapy with therapeutic drug monitoring (TDM) is widely recommended to avoid secondary clinical complications, such as vancomycin resistance due to under-dosing or toxicity caused by over-dosing [13].”
InfluentialPredicting Maintenance Doses of Vancomycin for Hospitalized Patients Undergoing Hemodialysis
Nekidy, W. S. E., El‐Masri, M. M., Umstead, G. S., & Dehoorne-Smith, M. L. (2016) · The Canadian Journal of Hospital Pharmacy · doi:10.4212/cjhp.v69i5.1588 · Cited by 13
Han, Z., Pettit, N. N., Landon, E. M., & Brielmaier, B. D. (2017) · Hospital Pharmacy · doi:10.1310/hpj5204-273 · Cited by 13
Young, T., Daniel, M., Baumhover, S., Eidson, D., & Green, J. (2017) · Drugs in R&D · doi:10.1007/s40268-017-0200-1 · Cited by 13
Impact of piperacillin/tazobactam on nephrotoxicity in patients with Gram-negative bacteraemia
Hall, R. G., Yoo, E., Faust, A. C., Smith, T., Goodman, E., Mortensen, E. M., Raza, J. A., Dehmami, F., & Álvarez, C. A. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.11.002 · Cited by 13
Using AUC/MIC to guide vancomycin dosing: ready for prime time?
Holmes, N. E. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.12.023 · Cited by 13
Emeka, P. M., Rasool, S. T., Morsy, M. A., Islam, M. I. H., & Chohan, M. S. (2021) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2021.25.4.321 · Cited by 17
“The results of cohort and retrospective studies have reported rising rates of nephrotoxicity due to the increased use of high-dose vancomycin [4,5].”
BackgroundEnsuring target concentrations of antibiotics in critically ill patients through dose adjustment
Gorham, J., Taccone, F. S., & Hites, M. (2022) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2022.2056012 · Cited by 14
Successful Utilization of High-Flux Hemodialysis for Treatment of Vancomycin Toxicity in a Child
Stidham, T., Reiter, P. D., Ford, D. M., Lum, G. M., & Albietz, J. A. (2011) · Case Reports in Pediatrics · doi:10.1155/2011/678724 · Cited by 13
Prescribing Habits of Vancomycin in the Emergency Department: Are We Dosing Appropriately?
Rosini, J. M., Grovola, M. R., Levine, B. J., & Jasani, N. B. (2013) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2012.11.051 · Cited by 14
Study Group of Infection in Critical Patients, Colomo, Ó. R., Lerma, F. Á., Pérez, M. I. G., Sirvent, J., & Simón, M. G. (2011) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-010-1133-6 · Cited by 13
“It is currently recommended that VAN trough plasma levels ranging from 15 to 20 μg/ml are achieved, and even higher levels if infection involves the CNS [25, 26].”
BackgroundInfluentialCies, J. J., Moore, W. S., Conley, S. B., Muneeruddin, S., Parker, J., SHEA, P. A., & Chopra, A. (2016) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000000656 · Cited by 17
Yoon, S., Park, K. R., Lee, S., Song, S., Park, W. B., Jang, I., & Yu, K. (2017) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12873 · Cited by 13
“Based on the new guideline recommendations on therapeutic drug monitoring (TDM) of vancomycin issued in 2009 [10], trough serum vancomycin concentrations should be maintained”
BackgroundElder, K., Hill, D. M., & Hickerson, W. L. (2017) · Burns · doi:10.1016/j.burns.2017.10.004 · Cited by 13
Significant publications on infectious diseases pharmacotherapy in 2013
Hunter, A. S., Guervil, D. J., Perez, K. K., Schilling, A. N., Verheyden, C. N., Vuong, N. N., & Xu, R. (2014) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp140148 · Cited by 13
Significant publications on infectious diseases pharmacotherapy in 2008
Kuper, K. M., Hirsch, E. B., & Tam, V. H. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp090099 · Cited by 15
Metadata
- Authors
- Rybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R., Craig, W., Billeter, M., Dalovisio, J. R., & Levine, D. P.
- Affiliations
- Eugene Applebaum College of Pharmacy and Health Sciences (US)
- Albany Medical Center Hospital (US)
- University of Minnesota (US)
- Beth Israel Deaconess Medical Center (US)
- University of Wisconsin–Madison (US)
- New Orleans, LA
- Ochsner Health System (US)
- Division of General Internal Medicine, WSU
- Corresponding author
- Rybak, Michael
- Venue
- American Journal of Health-System Pharmacy
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-01-01
- Volume
- 66
- Issue
- 1
- Pages
- 82-98
- ISSN
- 1079-2082 (ISSN-L)
- 1535-2900
- OpenAlex
- W2133120422
- Semantic Scholar
- f97f86b0eb5acbf0d7b5f8d4197a9e67f28c94ab
- Cited by
- 1,795
- References
- 130
- Citations by year
- 2026: 41 · 2025: 63 · 2024: 60 · 2023: 72 · 2022: 94 · 2021: 110 · 2020: 135 · 2019: 129 · 2018: 123 · 2017: 113 · 2016: 104 · 2015: 120 · 2014: 122 · 2013: 119 · 2012: 120
- FWCI
- 61.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Health-System Pharmacy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Keywords
- vancomycin, therapeutic drug monitoring, glycopeptides, methicillin-resistant Staphylococcus aureus, MRSA infection, Gram-positive bacterial infections, nephrotoxicity, ototoxicity, infusion-related toxicity, adverse drug reactions, pharmacokinetics, pharmacodynamics
- MeSH terms
- Adult, Anti-Bacterial Agents, Humans, Vancomycin, Drug Monitoring, Gram-Positive Bacterial Infections, Practice Guidelines as Topic, Vancomycin Resistance, Methicillin-Resistant Staphylococcus aureus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.